455 related articles for article (PubMed ID: 25910402)
1. Quinazoline derivatives as anticancer drugs: a patent review (2011 - present).
Ravez S; Castillo-Aguilera O; Depreux P; Goossens L
Expert Opin Ther Pat; 2015 Jul; 25(7):789-804. PubMed ID: 25910402
[TBL] [Abstract][Full Text] [Related]
2. Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).
Marzaro G; Guiotto A; Chilin A
Expert Opin Ther Pat; 2012 Mar; 22(3):223-52. PubMed ID: 22404097
[TBL] [Abstract][Full Text] [Related]
3. Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011-2016).
Hameed A; Al-Rashida M; Uroos M; Ali SA; Arshia ; Ishtiaq M; Khan KM
Expert Opin Ther Pat; 2018 Apr; 28(4):281-297. PubMed ID: 29368977
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor inhibitors: a patent review (2010 - present).
Li SN; Li HQ
Expert Opin Ther Pat; 2014 Mar; 24(3):309-21. PubMed ID: 24387079
[TBL] [Abstract][Full Text] [Related]
5. Recent development on naphthoquinone derivatives and their therapeutic applications as anticancer agents.
Tandon VK; Kumar S
Expert Opin Ther Pat; 2013 Sep; 23(9):1087-108. PubMed ID: 23651032
[TBL] [Abstract][Full Text] [Related]
6. Bestowal of Quinazoline Scaffold in Anticancer Drug Discovery.
Das R; Mehta DK; Dhanawat M
Anticancer Agents Med Chem; 2021; 21(11):1350-1368. PubMed ID: 32593282
[TBL] [Abstract][Full Text] [Related]
7. 2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014).
Leoni A; Locatelli A; Morigi R; Rambaldi M
Expert Opin Ther Pat; 2016; 26(2):149-73. PubMed ID: 26561198
[TBL] [Abstract][Full Text] [Related]
8. The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Li Y; Xiao J; Zhang Q; Yu W; Liu M; Guo Y; He J; Liu Y
Bioorg Med Chem; 2019 Feb; 27(3):568-577. PubMed ID: 30600149
[TBL] [Abstract][Full Text] [Related]
9. Novel thiazole derivatives: a patent review (2008 - 2012; Part 1).
Leoni A; Locatelli A; Morigi R; Rambaldi M
Expert Opin Ther Pat; 2014 Feb; 24(2):201-16. PubMed ID: 24215328
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Bansal R; Malhotra A
Eur J Med Chem; 2021 Feb; 211():113016. PubMed ID: 33243532
[TBL] [Abstract][Full Text] [Related]
11. Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature.
Mehndiratta S; Sapra S; Singh G; Singh M; Nepali K
Recent Pat Anticancer Drug Discov; 2016; 11(1):2-66. PubMed ID: 26681186
[TBL] [Abstract][Full Text] [Related]
12. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
14. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Das D; Hong J
Eur J Med Chem; 2019 May; 170():55-72. PubMed ID: 30878832
[TBL] [Abstract][Full Text] [Related]
15. Quinazoline compounds for antitumor treatment.
Solyanik GI
Exp Oncol; 2019 Mar; 41(1):3-6. PubMed ID: 30932417
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021-Present).
Abdel-Mohsen HT; Anwar MM; Ahmed NS; Abd El-Karim SS; Abdelwahed SH
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398626
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
18. A FGFR1 inhibitor patent review: progress since 2010.
Yu T; Yang Y; Liu Y; Zhang Y; Xu H; Li M; Ponnusamy M; Wang K; Wang JX; Li PF
Expert Opin Ther Pat; 2017 Apr; 27(4):439-454. PubMed ID: 27976968
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
